PROSPECTIVE GRANT OF AN EXCLUSIVE PATENT LICENSE: DEVELOPMENT AND COMMERCIALIZATION OF MIFEPRISTONE AND ANALOGUES TO TREAT HYPERCORTISOLISM-RELATED INSULIN RESISTANCE DISORDERS - FEDERALREGISTER

Patent license exclusivity signals commercial catalyst for mifepristone analogues in metabolic disorders.